/EXPRS2.ST
EXPRS2.ST Stock - ExpreS2ion Biotech Holding AB (publ)
Healthcare|BiotechnologySTO
$16.92-0.70%
$0.12 (-0.70%) • Dec 23
43
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.14
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $18.61
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EXPRS2.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.75 – $17.09
TARGET (TP)$19.46
STOP LOSS$15.57
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.64
52W High$34.20
52W Low$14.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.01M | $7.05M | $5.09M | $12.23M | $5.26M |
| Gross Profit | $-2,668,000 | $3.40M | $5,000 | $4.72M | $-843,000 |
| Gross Margin | -88.5% | 48.3% | 0.1% | 38.6% | -16.0% |
| Operating Income | $-67,695,000 | $-105,965,000 | $-127,606,000 | $-48,396,000 | $-31,196,000 |
| Net Income | $-36,038,000 | $-91,401,000 | $-118,605,000 | $-43,925,000 | $-31,713,000 |
| Net Margin | -1196.1% | -1296.5% | -2332.0% | -359.0% | -603.0% |
| EPS | $-21.31 | $-79.20 | $-125.60 | $-54.40 | $-66.40 |
Company Overview
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EXPRS2.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-3.18
Q3 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 19, 2026 | — | — | — | — |
Q3 2025 | Sep 30, 2025 | — | $-3.18 | — | — |
Q2 2025 | May 15, 2025 | — | $-5.14 | — | — |
Q1 2025 | Feb 6, 2025 | — | $-7.03 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-2.82 | — | — |
Q3 2024 | Aug 15, 2024 | — | $0.69 | — | — |
Q2 2024 | May 16, 2024 | — | $-10.00 | — | — |
Q1 2024 | Feb 8, 2024 | — | $-13.86 | — | — |
Q4 2023 | Nov 16, 2023 | — | $-17.60 | — | — |
Q3 2023 | Aug 17, 2023 | — | $-25.34 | — | — |
Q2 2023 | May 16, 2023 | — | $-27.98 | — | — |
Q1 2023 | Feb 9, 2023 | — | $-48.01 | — | — |
Q4 2022 | Nov 17, 2022 | — | $-30.50 | — | — |
Q3 2022 | Aug 18, 2022 | — | $-27.90 | — | — |
Q2 2022 | May 31, 2022 | — | $-15.65 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-16.20 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-11.90 | — | — |
Q3 2021 | Sep 17, 2021 | — | $-11.90 | — | — |
Q3 2021 | Jul 28, 2021 | — | $-14.09 | — | — |
Q1 2021 | Feb 25, 2021 | — | $-42.63 | — | — |
Latest News
Loading news...
Frequently Asked Questions about EXPRS2.ST
What is EXPRS2.ST's current stock price?
ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST) is currently trading at $16.92 per share. The stock has moved -0.70% today.
What is the analyst price target for EXPRS2.ST?
No analyst price targets are currently available for this stock.
What sector is ExpreS2ion Biotech Holding AB (publ) in?
ExpreS2ion Biotech Holding AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is EXPRS2.ST's market cap?
ExpreS2ion Biotech Holding AB (publ) has a market capitalization of $0.04 billion, making it a small-cap company.
Does EXPRS2.ST pay dividends?
No, ExpreS2ion Biotech Holding AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector2CUREX.ST
2cureX AB (publ)
$0.75
Mkt Cap: $0.0B
ACOU.ST
AcouSort AB (publ)
$2.64
Mkt Cap: $0.1B
AINO.ST
Aino Health AB (publ)
$0.18
Mkt Cap: $0.0B
FLUI.ST
Fluicell AB (publ)
$11.30
Mkt Cap: $0.0B
GUARD.ST
Guard Therapeutics International AB (publ)
$1.40
Mkt Cap: $0.0B
LPGO.ST
Lipigon Pharmaceuticals AB (publ)
$0.01
Mkt Cap: $0.0B
MODTX.ST
Modus Therapeutics Holding AB (publ)
$0.30
Mkt Cap: $0.0B
ONCOZ.ST
OncoZenge AB (publ)
$6.55
Mkt Cap: $0.1B
ORTI-B.ST
Ortivus AB (publ)
$1.21
Mkt Cap: $0.1B
SIMRIS-B.ST
Simris Alg AB (publ)
$0.05
Mkt Cap: $0.0B
Explore stocks similar to EXPRS2.ST for comparison